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Summary
Objective: To determine the effects of recombinant equine IL-1 and a number of antiinflammatory compounds on the expression and activity
of inducible nitric oxide synthase (iNOS) in cultured equine chondrocytes.
Design: RT-PCR methods were used to amplify a portion of the equine iNOS message to prepare an RNA probe. Northern blot analysis was
used to quantify the expression of iNOS in first passage cultures of equine articular chondrocytes propagated in the presence or absence
of recombinant equine interleukin-1 (reIL-1), dexamethasone (DEX), polysulfated glycosaminoglycan (PSGAG), hyaluronan (HA), and
phenylbutazone (PBZ), each at concentrations of 10 and 100 g/ml. Nitrite concentrations in conditioned media of similarly treated cells were
used to quantify iNOS activity.
Results: Recombinant equine IL-1 increased the expression of iNOS in a dose-dependent manner. This result was paralleled by an
increased concentration of nitrite in the culture media of reIL-1-treated cells. DEX and PSGAG significantly reduced iNOS gene expression
and media supernatant nitrite concentrations in cytokine-stimulated cultures. HA and PBZ had no consistent effect on the expression of iNOS
and did not significantly influence nitrite content of conditioned media.
Conclusions: NO is considered an important mediator in the pathophysiologic processes of arthritis and an inducible NOS is expressed by
equine chondrocytes. Pre-translational regulation of the iNOS gene by DEX and PSGAG appears to contribute to the cartilage-sparing
properties of these compounds. © 2002 OsteoArthritis Research Society International
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Osteoarthritis (OA) is a well-known and expensive problem
for the equine athlete that causes substantial morbidity in
the form of lameness which may seriously curtail the quality
of life and athletic serviceability of affected horses. The
hallmark of the disease is the degeneration of articular
cartilage, a highly specialized tissue consisting of relatively
few cells but having a rich extracellular matrix composed of
collagens and proteoglycans. Contrary to earlier beliefs, it
is now known that articular cartilage is a metabolically
active tissue and that chondrocytes are capable of both
synthesizing and digesting matrix macromolecules, thus
providing a means for maintaining the cartilage matrix in a
healthy state. Under normal circumstances, there is an
equilibrium between matrix deposition and degradation,
however this equilibrium is disrupted in OA leading to the5excessive digestion of matrix and progressive loss of
important matrix components1,2. Several influences are
believed to be responsible for this imbalance in chondro-
cyte metabolism in OA, and proinflammatory cytokines
appear to be among the most important. For example,
interleukin-1 (IL-1) causes reduced chondrocyte synthesis
of aggrecan and encourages a change in chondrocyte
collagen synthesis from a cartilagenous (type II) to a fibrous
tissue form (type I)3. In addition to their deleterious influ-
ence on matrix synthesis in cartilage, IL-1 and other pro-
inflammatory mediators accelerate the degradation of the
matrix by inducing the synthesis of proteolytic enzymes, the
most important of which are believed to be the matrix
metalloproteinases (MMPs).
An inflammatory mediator presently undergoing intense
study is nitric oxide (NO). This highly reactive, cytotoxic
free radical is a by-product of the oxidation of L-arginine to
citrulline, catalyzed by a group of enzymes called NO
synthases (NOS). Nitric oxide synthases exist in a number
of forms and in a wide array of tissues. It has been shown
that there are constitutive forms of NOS (cNOS) respon-
sible for continuous low levels of synthesis and inducible
forms (iNOS) which produce large amounts of the mediator
when cells expressing this enzyme are activated by media-
tors such as endotoxins and other bacterial products, and
cytokines4–6.
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arthritic process and its lesions. Early evidence for the
involvement of this mediator in rheumatic diseases was
the observation that nitrite, a stable end-product of NO, was
found in elevated concentrations in the synovial fluid and
serum of rheumatoid arthritis patients7. Moreover, osteo-
arthritic cartilage spontaneously produces NO, probably
reflecting the in vivo stimulation of chondrocytes by
cytokines8–10. It appears that the important quantities of
NO liberated in arthritic joints are mainly of chondrocytic
origin8–12, and chondrocytes in superficial cartilage layers
are a particularly rich source of the molecule13. Nitric oxide
is hypothesized to contribute to a number of the deleterious
influences of IL-1 on cartilage metabolism including
augmented expression and activation of MMPs14,15, and
reduced synthesis of the natural receptor antagonist
protein for IL-110. Accumulating evidence also implicates
NO in the inhibition of chondrocyte synthetic activities that
occur in OA. Specifically, proteoglycan and type 2 collagen
synthesis are inhibited under conditions conducive to NO
formation16–19.
In models of inflammatory arthritis, treatment with
compounds that directly or indirectly inhibit iNOS activity
have been shown to reduce the severity of lesions20–22.
Similarly, in an established canine OA model, treatment
with N-iminoethyl-L-lysine, a selective inhibitor of iNOS,
resulted in a significant reduction of arthritis lesions of
cartilage and synovial membrane23. Moreover, treated
dogs had significantly reduced MMP activity in cartilage
extracts, paralleled by a reduced immunostaining of
chondrocytes for stromelysin 1 and collagenase 1, in
addition to reduced concentrations of IL-1 and NO
metabolites in the synovial fluid and tissues23,24. These
data suggest that inhibition of NO release may attenuate
the progression of OA by reducing MMP synthesis in
cartilage. If these effects occur in naturally occurring OA in
horses, selective iNOS inhibition could hold considerable
promise in therapy for this important disease.
A variety of compounds are commonly used in the
symptomatic treatment of equine OA including cortico-
steroids, non-steroidal antiinflammatory drugs and the
putative disease-modifying (chondroprotective) agents
such as hyaluronan and polysulfated glycosaminoglycan.
Recent studies, using cartilage or chondrocytes from a
number of species, have demonstrated that each of the
above compounds, including corticosteroids, have certain
cartilage-sparing properties. For example, at low doses,
corticosteroids are capable of reducing cartilage degrada-
tion, ostensibly by inhibiting the synthesis of matrix metal-
loproteinases and cytokines25,26. Similarly, phenybutazone
and hyaluronan have been shown to reduce matrix loss
from cartilage explants in culture27,28. Polysulfated glycos-
aminoglycans have been proposed as putative disease-
modifying treatment, initially attributed to anabolic effects
on cartilage metabolism29. Subsequent experiments using
normal and mildly osteoarthritic equine cartilage failed to
support substantial effects on aggrecan synthesis and
beneficial effects of polysulfated glycosaminoglycans are
currently regarded as largely due to reduced proteolytic
enzyme activity30–32.
While often effective in reducing lameness, and possess-
ing at least some cartilage sparing potential, the specific
roles of these and other medications in retarding the
progression of OA lesions remains unclear. While contin-
ued efforts are being directed at studying the role of these
drugs in modulating the pathophysiologic processes of
equine OA, there remains uncertainty regarding their pre-cise mechanisms of action. A potential means by which
some or all of these compounds may provide symptomatic
relief and/or chondroprotection or both may be by modify-
ing the synthesis or actions of NO.
The purpose of the study presented here was to charac-
terize the expression of equine iNOS in chondrocytes in
stationary culture and to determine if iNOS expression or
activity or both are influenced by commonly prescribed
antiarthritis compounds in short-term reIL-1-stimulated
cultures.Materials and methods
TISSUE SOURCES AND CELL CULTURE
Grossly normal metacarpophalangeal articular cartilage
was obtained from adult horses (2–8 years) sacrificed for
reasons other than musculoskeletal disease. Cartilage was
dissected from the subchondral bone, and chondrocytes
were isolated by sequential digestion with pronase and
collagenase as previously described, with minor modifica-
tions25. High density monolayer cultures were established
in Dulbecco’s modified Eagle’s medium, with 10% fetal
bovine serum and penicillin and streptomycin under stan-
dard culture conditions. Experiments were performed using
first-passage, high-density cultures.EXTRACTION OF RNA AND CDNA SYNTHESIS
Total RNA was extracted, using a commercial extraction
preparation* and following the manufacturer’s instructions.
Briefly, this agent was added to each well after washing the
cells with cold phosphate-buffered saline solution (PBS)
and, after an incubation of 5 min at 25°C, the solution was
transferred to centrifuge tubes to which was added chloro-
form (0.2 ml/ml of base reagent), followed by vigorous
agitation and a second incubation (10 min, 22°C). After
centrifugation (12,000×g, 4°C), the aqueous phase was
removed and the RNA was precipitated with isopropanol,
then the pellet was washed with 75% ethanol. The RNA
was re-centrifuged and the pellet was resuspended in
diethyl pyrocarbonate treated sterile water and quantified
spectrophotometrically.AMPLIFICATION OF CDNA AND PROBE PREPARATION AND
SEQUENCING
Complementary DNA was synthesized, using reverse
transcriptase-polymerase chain reaction (RT-PCR) with
2 g of total RNA from a chondrocyte culture that had been
stimulated (6 h) with recombinant equine IL-1 at 10 ng/ml.
A specific set of oligonucleotide primers for the iNOS gene
were synthesized on the basis of the published human and
rodent iNOS cDNA sequences33,34 and was used at a final
concentration of 3 pM/l. The sequences for the iNOS
primers were 5′-GTT CCC CCA GCG GAG TGA-3′ (sense
primer), starting at position 738 bp of the published
sequence of the human gene, and 5′-TCT TTC CAG AGG
GAG GCC A-3′ (antisense primer) and ending at position
1235 bp. Amplification by PCR produced 497 bp cDNA
fragment of the putative iNOS gene, which, after purifi-
cation, was directionally ligated directly to pBluescript-
SK±vector. An RNA probe was produced from the clone*Trizol Reagent, Gibco BRL, Grand Island, NY.
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dUTP.* Sequencing of the probe was performed using
manual methods.STIMULATION WITH REIL-1
To test the influence of reIL-1 on the expression of
iNOS in normal equine chondrocytes, confluent cultures of
first passage cells from two horses were grown to conflu-
ence in individual six-well plates (1×106 cells/well) and
were stimulated for 8 h with reIL-1 (0, 1, 5, 10, 50,
100 ng/ml), followed by RNA extraction and Northern blot
hybridization. To characterize the temporal aspects of iNOS
expression, similar cultures were treated with 10 ng/ml
reIL-1 for 0, 2, 4, 6, 8, 12 h, followed by RNA isolation and
Northern blot hybridization.TREATMENT WITH ANTIARTHRITIS COMPOUNDS
Cultures derived from three horses were used in this
portion of the study. First-passage chondrocytes, derived
from metacarpophalangeal joints with grossly normal
articular cartilage were grown to confluence in six-well
plates. After a period of 3–5 days of culture under serum-
free conditions, each well received one of a number of
randomly-assigned treatments consisting of control (no
additives); reIL-1 (10 ng/ml) and one of dexamethasone
(DEX) (10−6 M and 10−5 M), hyaluronan (HA) (10 and
100 g/ml), polysulfated glycosaminoglycan (PSGAG) (10and 100 g/ml), or phenylbutazone (PBZ) (10 and 100 g/
ml) in the presence and absence of reIL-1 (10 ng/ml)
(Table I). After 6 h incubation, RNA was extracted for
Northern blotting. Conditioned media from similarly treated
24 h cultures, using cartilage from three different animals,
were used for the indirect determination of NO. To ensure
that treatments did not have cytotoxic effects, a live-dead
assessment was conducted on each treatment well of a
single culture, using a commercially-available kit following
manufacturer’s directions.§NITRITE CONCENTRATIONS IN CONDITIONED MEDIA
Nitric oxide synthase activity was indirectly determined
by measuring the stable end product NO2 using a spectro-
photometric method35. Briefly, 200 l aliquots of culture
medium were added to an equal volume of a freshly
prepared mixture of equal proportions of 1% sulfanilamide
and 0.1% naphthylethylenediamine dihydrochloride. The
absorbance of the solution was read at 550 nm after a
30 min incubation and NO2 concentrations were deter-
mined using a standard curve.
To investigate the possibility that one or more treatment
may have caused a disproportionate synthesis of either
nitrite or nitrate by NO, nitrate in conditioned media was
converted to nitrite using nitrate reductase in an NADPH
system as previously reported36. Briefly, 200 l aliquots of
culture medium were incubated with NADPH (40 M) and
nitrate reductase\ (14 mU) in 20 mM Tris for 15 min (20°C),
after which the reaction was terminated by the addition ofTable I
First-passage chondrocytes, derived from joints with grossly nor-
mal articular cartilage were grown to confluence in six-well plates
Treatment
number
Treatment Dose re IL-1
(10 ng/ml)
1 Negative control — −
2 Positive control — +
3 Dexamethasone control-1 10−6 M −
4 Dexamethasone control-2 10−5 M −
5 Dexamethasone—reIL1 10−6 M +
6 Dexamethasone—reIL1 10−5 M +
7 PSGAG control-1 10 g/ml −
8 PSGAG control-2 100 g/ml −
9 PSGAG—reIL1 10 g/ml +
10 PSGAG—reIL1 100 g/ml +
11 Hyaluronan control-1 10 g/ml −
12 Hyaluronan control-2 100 g/ml −
13 Hyaluronan—reIL1 10 g/ml +
14 Hyaluronan—reIL1 100 g/ml +
15 Phenylbutazone control-1 10 g/ml −
16 Phenylbutazone control-2 100 g/ml −
17 Phenylbutazone—reIL1 10 g/ml +
18 Phenylbutazone—reIL1 100 g/ml +
(PSGAG: polysulfated glycosaminoglycan; reIL-1: recombinant
equine interleukin-1.)
After a period of 3–5 days of culture under serum-free con-
ditions, each well received one of the treatments listed above.
After 6 h incubation, RNA was extracted for Northern blotting.
Conditioned media from similarly treated 24 h cultures were used
for the indirect determination of NO (Greiss reaction).*DIG High Prime DNA Labeling and Detection Starter Kit II,
Roche Molecular Biochemicals, Indianapolis, IN.
†Nylon Membranes (positively charged), Roche Molecular Bio-
chemicals, Indianapolis, IN.
‡Scion Image Beta 4.02, Scion Corp, Frederick, MD.§Live/Dead Viability/Cytotoxicity Kit, Molecular Probes, Eugene,
OR.
\Nitrate reductase, Sigma Chemical, St Louis, MO.NORTHERN BLOT HYBRIDIZATION
Northern blot hybridization was conducted as previously
described25. Total chondrocyte RNA was resolved on 1.2%
agarose-formaldehyde gels, using 4 g of RNA. After over-
night transfer to nylon membranes,† RNA was cross-linked
to the membranes by exposure to UV light. After prehybridi-
zation (1 h, 68°C) in a saline-sodium citrate-based (SSC)
buffer, the membranes were hybridized overnight at 68°C in
35 ng of labeled probe/ml. Serial post-hybridization washes
were carried out at 68°C, with decreasing concentrations of
SSC buffer, followed by brief washing in a maleic acid
buffer. Detection was accomplished, using a chemilumi-
nescent method with digoxigenin-11-uridyl triphosphate
and Lumigen (4-methoxy-4-(3-phophatephenyl)spiro-1,2-
dioxetane-3,2′-adama ntane (disodium salt) as a substrate
for alkaline phosphatase conjugated to digoxygenin anti-
body Fab fragments, as described by the manufacturer,
with slight modifications. The membranes were then sub-
jected to autoradiography at room temperature for 15 min.
Autoradiographic films were scanned using a desktop
scanner and the intensity of each band was quantified
using image acquisition and analysis software to determine
relative mRNA abundance.‡ Standardization against the
corresponding values for ethidium bromide-stained 28S
ribosomal RNA enabled semiquantitative evaluation of
specific mRNA (i.e., expression of iNOS was calculated as
the ratio of the intensity of the iNOS bands to the intensity
of the 28S rRNA band).
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as previously described.
ANALYSIS OF DATA
Comparison of means for relative expression of iNOS as
well as media concentrations of nitrite were performed
using a two-way ANOVA (blocked by horse) followed by a
Dunnett’s test. A P value <0.05 was considered significant.ResultsAMPLIFICATION OF CDNA
The 497-bp fragment of equine iNOS amplified by use of
RT-PCR cDNA had approximately 88% sequence identity
with the human cDNA sequence and 92% identity of the
deduced amino acid sequence indicating that the cloned
fragment is a portion of the corresponding equine iNOS
message. (GenBank accession number AF329377).STIMULATION WITH REIL-1
Northern blot analysis, using the equine iNOS probe,
showed a 4.6 kb positively hybridizing band from activated
equine chondrocytes. Subsequent studies indicated a
dose-dependent stimulatory effect of reIL-1 on iNOS
expression (Fig. 1). Temporal studies indicated that iNOS
expression was rapidly up-regulated by reIL-1 (Fig. 2).EFFECTS OF ANTIINFLAMMATORY COMPOUNDS ON INOS
EXPRESSION
Evaluation of cell viability using a calcein/ethidium-based
live/dead assay revealed negligible cell death with any
treatment combination (data not shown). None of the
antiarthritis compounds influenced resting expression of
iNOS. DEX, at both 10−6 and 10−5 M, markedly reduced
reIL-1-induced up-regulation of iNOS expression (Fig. 3).
A similar effect was observed for PSGAG; this compound
also significantly reduced reIL-1-stimulated iNOS expres-
sion at both doses tested (10 and 100 g/ml). Neither HA
nor PBZ had a statistically-significant effect on iNOS
expression in cytokine-stimulated cultures.EFFECTS OF ANTI-INFLAMMATORY COMPOUNDS ON INOS ACTIVITY
Nitrate conversion was conducted on media superna-
tants from a single horse to ensure that disproportionate
production of either nitrate or nitrite influenced the indirect
determination of NO activity. Because results following
nitrate conversion closely paralleled those using nitrite
concentration alone, Greiss reaction values (nitrite) on
unconverted supernatants were conducted and are
reported. Statistical analyses of these data from 24 h
cultures paralleled our findings for RNA expression.
Specifically, spent media from cultures treated with DEX at
both concentrations tested and PSGAG at both 10 and
100 g/ml had nitrite concentrations that were significantly
less than those of cytokine-treated controls (Fig. 4).
Cytokine-stimulated cells exposed to HA and PBZ had
media nitrite concentrations comparable to reIL-1-treated
controls. (Fig. 4).Fig. 1. Representative Northern blot of iNOS expression by normal
equine chondrocytes stimulated with increasing doses of recom-
binant equine interleukin-1 (reIL-1). Total RNA (4 g) was
resolved on formaldehyde agarose gels as described in Materials
and Methods. Blots were probed with a digoxigenin-labeled iNOS
RNA probe. Interleukin-1 concentrations (ng/ml) are given below
the corresponding lane. The position of the iNOS message with
respect to the rRNA bands is indicated to the right of the iNOS
bands. The corresponding ethidium bromide-stained 28S rRNA
bands are shown below.Fig. 2. Representative Northern blot showing temporal aspects of
up-regulation of iNOS expression by normal equine chondrocytes
stimulated with 10 ng of reIL-1. Total RNA (4 g) was resolved
on formaldehyde agarose gels as described in Materials and
methods. The duration of exposure (h) of the cultures to the
cytokine prior to RNA isolation is indicated beneath each of
the iNOS bands. The position of the iNOS message with respect to
the rRNA bands is indicated to the right of the iNOS bands. The
corresponding ethidium bromide-stained 28S rRNA bands are
shown below.Discussion
While the role of NO in the physiology and pathobiology
of equine vascular reactivity and neuromuscular transmis-
sion in a number of organ systems has been the subject
of recent research, its role in equine OA pathogenesis
has received little study. We prepared an RNA probe to
characterize an inducible member of the NOS family that
corresponds to a similarly-sized cDNA demonstrated in
cytokine-stimulated human chondrocytes37. Results of sub-
sequent short-term experiments using reIL-1-stimulated
cultures complement previous reports describing NO syn-
thesis by equine chondrocytes in response to stimulation
with proinflammatory mediators11,38. We also provide
data indicating that chondrocyte iNOS expression and
activity are influenced by corticosteroids and polysulfated
glycosaminoglycans.
We observed a marked and rapid up-regulation of iNOS
expression in chondrocytes by reIL-1, an event that is
hypothesized to contribute to the pathophysiologic events
and lesions of OA; however the specific contribution(s) of
NO to IL-1-induced cartilage matrix depletion is controver-
sial. Early laboratory studies revealed that the MMP activity
in IL-1 and TNF-stimulated bovine and human chondro-
cyte and explant cultures was enhanced by NO donors in a
dose-dependent fashion15, an effect that was inhibited in
the presence of competitive inhibitors of NOS. Similar
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Fig. 3. Effects of antiarthritis preparations on reIL-1-stimulated iNOS expression by normal chondrocytes. IL-1-stimulated control and
treated cultures have filled bars and non-stimulated controls have open bars. Specific treatments are given in Table I. Inducible NOS
expression was calculated as the ratio of the intensity of the iNOS bands to the intensity of the ethidium bromide-stained 28S ribosomal RNA
band of the electrophoretic gel. Values are mean (±S.E.M.) expression from three experiments. Relative expression of reIL-1-stimulated
iNOS in chondrocytes treated with dexamethasone (10−6 M and 10−5 M) and polysulfated glycosaminoglycan (polysulfated GAG) (10 g/ml,
and 100 g/ml) (marked by asterisks) was significantly (P<0.05) less than that of reIL-1-stimulated (positive control) cells.0
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Fig. 4. Effects of antiarthritis preparations on reIL-1-stimulated nitric oxide synthase activity (nitrite concentration in conditioned media) by
normal chondrocytes as determined by the Greiss reaction. IL-1-stimulated control and treated cultures have filled bars and non-stimulated
controls have open bars. Specific treatments are given in Table I. Values are mean (±S.E.M.) expression from three experiments. Nitrite
accumulation in spent media from chondrocytes treated with dexamethasone (10−6 M and 10−5 M) and polysulfated glycosaminoglycan
(10 g/ml, and 100 g/ml) (marked by asterisks) was significantly (P<0.05) less than that of reIL-1-stimulated (positive control) cells.findings were reported using rabbit chondrocytes; an NO
inhibitor abrogated MMP induction of by IL-114. Conversely,
the cytokine-mediated induction of MMP expression wasobserved independently of stimulation by NO39. More-
over, cytokine-stimulated cartilage explants cultured in the
presence of NO inhibitors have been reported to have
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and a protective effect of NO on proteoglycan depletion has
been observed in early, but not late, explant cultures of
bovine chondrocytes18,40. Apparent disparities in these
findings may be due to experimental design, species differ-
ences, temporal effects, relative concentrations of NO and
cytokines, and the presence or absence of undetected
ancillary mediators.
Although the specific molecular and cellular actions and
interactions of NO on MMP expression and cartilage deg-
radation remain to be determined, in vivo arthritis models
provide important evidence implicating NO in articular
pathobiology. For example, a recent study using an inflam-
matory arthritis model in iNOS-deficient mice revealed that
genetically-disrupted mice had reduced proteoglycan
depletion as well as fewer cartilaginous lesions and osteo-
phytes than normal mice41. Similar findings have been
observed using an established canine OA model23,24, sup-
porting a major role for NO in cartilage damage in joint
diseases.
Northern blot analyses indicated that expression of our
chondrocyte iNOS was inhibited by dexamethasone at
10−6–10−5 M. In other species, a number of isoforms of
NOS have been described and vary in their sensitivity to
glucocorticoids29,42. Many iNOS isolated from mammalian
chondrocytes are insensitive to corticosteroids at modest
doses, however, paralleling our findings, bovine iNOS
expression is inhibited with high doses of dexametha-
sone12. These findings may suggest a limited influence of
endogenous glucocorticoids on iNOS expression but that
pharmacologic doses are inhibitory.
PSGAG was observed to reduce reIL-1-induced
expression of iNOS. While polysulfated glycosamino-
glycans are generally considered effective for the sympto-
matic treatment of OA in humans and animals, the mecha-
nism(s) of action of PSGAG in pain relief and disease
modification (chondroprotection) remain to be confirmed.
Based on our results, it is possible that, in addition to other
potential effects, the chondroprotective potential of PSGAG
may be due to their ability to inhibit the expression of iNOS.
It has been shown that heparinoids are capable of influenc-
ing gene expression in connective tissue mesenchyme. A
recent report indicates that heparin down-regulates MMP
expression in human gingival fibroblasts43 and it has been
shown that heparin and pentosan polysulfate, a sulfated
glycosaminoglycan of plant origin, down-regulate phorbol-
induced cancer cell proliferation by interfering with the
binding of transcription factor to gene promoter AP-1
sites44. PSGAG may down-regulate equine iNOS by similar
mechanisms. Inhibition of NO synthesis or activity has
been recently reported for other putative antiarthritis
agents. For example, in acute experiments, glucosamine,
an aminomonosaccharide, significantly inhibited NO syn-
thesis by lipopolysaccharide-stimulated equine articular
cartilage explants45, and doxycycline (a tetracycline deriva-
tive) reduces the expression of iNOS in human chondro-
cytes46, providing an potential explanation for the beneficial
effects of these compounds in some arthritis models.
Hyaluronan is a glycosaminoglycan composed of
the disaccharides D-glucuronic acid and N-acetyl-D-
glucosamine. It has been shown to have beneficial effects
in the treatment of incipient joint disease in horses and
laboratory studies have demonstrated its ability to inhibit
matrix degradation in IL-1-activated chondrocytes by
mechanisms yet to be determined28,47. In this study, mean
relative expression of iNOS in cytokine/hyaluronan treated
cultures was approximately half that of the positive (reIL-1) controls, however this difference was not statistically
significant. It is possible that with greater replication this
phenomenon may have approached statistically signifi-
cance and a potential effect of hyaluronan on iNOS expres-
sion cannot be ruled out based on this study. Nevertheless,
reIL-1-stimulated chondrocytes exposed to HA produced
nitrite in quantities comparable to reIL-1 controls. This
latter finding suggests that, under these experimental con-
ditions, a biologically significant effect of HA on net NO
activity was absent. Previous research has indicated that
HA may be delayed in its actions and the possibility
that a more prolonged exposure to HA may have produced
different results remains to be investigated. Nonetheless,
HA has been shown to have effects on the synthetic
activities of synovial fibroblasts and chondrocytes cultured
under similar conditions and with comparable incubation
times47–49. Interestingly, of several glucosamine salts
tested for inhibitory activity against NO, N-acetyl-D-
glucosamine, the hexosamine comprising half the residues
of hyaluronan, possessed no such activity in lipopoly-
saccharide-stimulated equine articular cartilage explants50.
Experimental results for phenylbutazone were similar
effects to those of hyaluronan in this study. Specifically,
mean expression in cytokine/PBZ-treated cultures was
reduced by nearly half, yet nitrite content in conditioned
media was not substantially different. While it appears that
phenylbutazone is capable of limiting the proteoglycan
depletion that accompanies in vitro cartilage culture27, our
data suggest that the effect is unlikely to be due to
modulation of iNOS synthesis or activity. Limited data is
available with respect to the influence of various NSAIDs
on iNOS expression, however transcriptional influences of
NSAIDs on iNOS expression have been reported. Specifi-
cally, rhein and diacerhein have been reported to regulate
iNOS mRNA expression in IL-1-stimulated osteoarthritic
human chondrocytes51. The identity and precise mechan-
ism(s) of action of various NSAIDs on iNOS synthesis and
activity remain to be determined.
In summary, the results of this study provide previously
unreported data on the modulation of equine iNOS expres-
sion and activity. These data parallel findings reported
using tissues from other species, support a role for NO
in the pathogenesis of equine OA, and provide new infor-
mation concerning mechanisms of action of antiarthritis
drugs used in horses.References
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